tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

CANF Stock Latest News

Can-Fite Advances Pancreatic Cancer Drug Trial
Company AnnouncementsCan-Fite Advances Pancreatic Cancer Drug Trial
4d ago
6K
CANF
Can-Fite received approval from Israeli MoH to conduct Phase IIa trial
PremiumThe Fly
Can-Fite received approval from Israeli MoH to conduct Phase IIa trial
4d ago
CANF
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
PremiumPress Releases
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
4d ago
CANF
Can-Fite BioPharma Launches $9M ADS Offering
PremiumCompany Announcements
Can-Fite BioPharma Launches $9M ADS Offering
21d ago
6K
CANF
Can-Fite BioPharma files to sell 1.77B ordinary shares for holders
PremiumThe Fly
Can-Fite BioPharma files to sell 1.77B ordinary shares for holders
21d ago
CANF
Can-Fite Advances Therapeutic Pipeline Amidst Market Opportunities
PremiumCompany AnnouncementsCan-Fite Advances Therapeutic Pipeline Amidst Market Opportunities
22d ago
6K
CANF
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
Premium
Press Releases
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
22d ago
CANF
Can-Fite BioPharma reports 1H24 EPS 0c vs. 0c last year
Premium
The Fly
Can-Fite BioPharma reports 1H24 EPS 0c vs. 0c last year
22d ago
CANF
Is CANF a Buy, Before Earnings?
PremiumPre-Earnings
Is CANF a Buy, Before Earnings?
24d ago
CANF
Can-Fite BioPharma Proposes Warrant Exercise Incentives
PremiumCompany Announcements
Can-Fite BioPharma Proposes Warrant Exercise Incentives
1M ago
6K
CANF
Can-Fite BioPharma Raises $5 Million
PremiumCompany Announcements
Can-Fite BioPharma Raises $5 Million
1M ago
6K
CANF
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
PremiumPress Releases
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
1M ago
CANF
Can-Fite’s Namodenoson Secures Patent Until 2044
PremiumCompany AnnouncementsCan-Fite’s Namodenoson Secures Patent Until 2044
2M ago
6K
CANF
Can-Fite Provides Namodenoson Patent Update
Premium
Press Releases
Can-Fite Provides Namodenoson Patent Update
2M ago
CANF
Can-Fite BioPharma provides Namodenoson patent update
Premium
The Fly
Can-Fite BioPharma provides Namodenoson patent update
2M ago
CANF
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
PremiumPress Releases
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
2M ago
CANF
Can-Fite BioPharma initiated with a Buy at EF Hutton
PremiumThe Fly
Can-Fite BioPharma initiated with a Buy at EF Hutton
2M ago
CANF
Can-Fite Seeks FDA Nod for Cancer Drug Namodenoson
PremiumCompany Announcements
Can-Fite Seeks FDA Nod for Cancer Drug Namodenoson
2M ago
6K
CANF
Can-Fite BioPharma applies for FDA Orphan Drug Designation for namodenoson
PremiumThe Fly
Can-Fite BioPharma applies for FDA Orphan Drug Designation for namodenoson
2M ago
CANF
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
PremiumPress ReleasesCan-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
2M ago
CANF
Can-Fite BioPharma Shareholders Approve Key Proposals
Premium
Company Announcements
Can-Fite BioPharma Shareholders Approve Key Proposals
3M ago
6K
CANF
Can-Fite Reports Positive Liver Cirrhosis Treatment Results
Premium
Company Announcements
Can-Fite Reports Positive Liver Cirrhosis Treatment Results
3M ago
6K
CANF

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >